Hekmat Bechir Antaki (H. Antaki)

H. B. F. Antaki, Cairo, circa 1960s

Biography

Hekmat Bechir Fathallah Antaki was an Egyptian organic chemist. He completed his doctoral degree at Queen Mary College, University of London, in 1950, under the supervision of J.R. Partington. He returned to Egypt and joined the Research Institute for Tropical Medicine, Cairo, where he conducted an independent programme of research in heterocyclic chemistry between 1951 and 1967. He subsequently served as Director of the Research Institute of Medical Entomology, Cairo.

He published eight papers in four leading chemistry journals between 1951 and 1967. Working without university affiliation, he developed multicomponent condensation methods for the synthesis of pharmacologically relevant heterocyclic scaffolds. His 1962 paper was submitted from his home address in Agouza, Cairo — self-funded research by a working scientist.

His published work was characterized by rigorous bibliographic integrity. His 1965 paper cited foundational research dating back to Bongartz (1888), Stobbe and Volland (1902), and Colange, Dreux and Delplace (1957) — tracking sources spanning 76 years without access to electronic databases, digital libraries, or search engines. Working from Cairo, with whatever physical library resources were available, he credited prior work precisely and completely. He did not claim what was not his.

The Two Privileged Scaffolds

Across eight papers, Antaki's work established two heterocyclic scaffolds, each now recognised in medicinal chemistry.

What the Field Said

Independent parties — patent attorneys, review authors, and research chemists — described his work in their own words. None was obliged to mention him.

"The synthesis of a 1H-pyrimido[1,2-a]quinoline appears to have first been reported by Antaki et al., J. Chem. Soc., pp. 551–555 (1951)."
— Pfizer, US 4,066,766 (1978)

"hexahydroquinoline derivatives… aroused our interest."
— Bossert and Vater, inventors of nifedipine, citing Antaki's 1963 paper at that step. Medicinal Research Reviews 9, 291 (1989).

Products of 4-methylpyridine and ethoxymethylene cyanoacetate "were first described by Antaki."
— Hermecz and Mészáros, the canonical review of the ring system. Advances in Heterocyclic Chemistry, Vol. 33 (1983).

Their products were "identical in m.p., ir, uv, and pmr spectra… as described by Antaki and Petrow" — confirmed by X-ray crystallography and NMR.
— Yale, Toeplitz, Gougoutas and Puar, Squibb Institute for Medical Research. J. Heterocyclic Chem. (1972/73).

"Suitable reaction conditions are also reported by Antaki in J. Chem. Soc., 4877 (1963)."
— Zeneca, EP 0539154 (1997).

The full record — patents, reviews, reference works, and laboratory use, in their authors' own words: In Their Own Words

Recognition and Record

• Named reaction. His 1963 hexahydroquinoline synthesis has been formally classified as the Antaki synthesis, alongside the Hantzsch and Stankevich reactions, as one of three foundational multicomponent methods for that scaffold class. Oduselu et al., Frontiers in Chemistry, 2026. DOI: 10.3389/fchem.2026.1769586

  "Traditional multicomponent reactions such as the Hantzsch, Antaki, and Stankevich methods are discussed alongside more recent green synthetic strategies." — Oduselu et al., Frontiers in Chemistry, 2026.

• Pharmaceutical patents. Twenty-five confirmed citations in pharmaceutical patent filings, verified at text level. From ICI (Imperial Chemical Industries) in US 5,258,390 (1993):

  "The compounds of formula I wherein R is 5-nitro-2-furyl, 3-nitrophenyl and 4-nitrophenyl are known, for example from… Antaki, J. Chem. Soc., 4877 (1963)."

  "Suitable reaction conditions are also reported by Antaki in J. Chem. Soc., 4877 (1963)." — US 5,258,390, Imperial Chemical Industries PLC, 1993.

  #	Patent	Assignee	Published	Paper cited
  1	US 3,538,086	CIBA (Switzerland)	1970-11-03	1951 JCS
  2	US 4,014,881	Pfizer	1977-03-29	1951 JCS + 1958 JACS
  3	US 4,017,625	Pfizer	1977-04-12	1951 JCS + 1958 JACS
  4	US 4,022,897	E.R. Squibb	1977-05-10	1951 JCS
  5	US 4,031,217	Pfizer	1977-06-21	1951 JCS + 1958 JACS
  6	US 4,041,163	Pfizer	1977-08-09	1951 JCS
  7	US 4,066,766	Pfizer	1978-01-03	1951 JCS + 1958 JACS
  8	US 4,122,274	Bristol-Myers	1978-10-24	1958 JACS
  9	US 4,209,620	Bristol-Myers	1980-06-24	1958 JACS
  10	US 4,223,031	Mead Johnson	1980-09-16	1951 JCS
  11	US 4,491,587	Mead Johnson	1985-01-01	1951 JCS
  12	US 5,166,206	Merck	1992-11-24	1951 JCS
  13	EP 0539153	Zeneca	1993	1963 JCS
  14	EP 0539154	Zeneca	1993	1963 JCS
  15	US 5,258,390	ICI/AstraZeneca	1993-11-02	1963 JCS
  16	CA 2080950	ICI / Zeneca	1993	1963 JCS
  17	CA 2080949	ICI / Zeneca	1993	1963 JCS
  18	US 5,324,729	Merck	1994-06-28	1951 JCS
  19	US 5,340,819	ICI	1994-08-23	1951 JCS
  20	US 5,455,253	Zeneca	1995-10-03	1963 JCS
  21	US 5,484,792	ICI	1996	1963 JCS
  22	US 5,622,964	Zeneca	1997-04-22	1963 JCS
  23	US 8,716,319	Gilead Sciences	2014-05-06	1963 JCS
  24	WO 2015/002150	Shin Nippon Biomedical Labs	2015-01-08	1951 JCS
  25	US9745274	Shin Nippon Biomedical Labs	2017-08-29	1951 JCS

  The most recent granted patent — US9745274, Shin Nippon Biomedical Laboratories, Japan, granted 2017 — cites the 1951 paper as prior art and remains in force until 2034: eighty-three years after the paper's publication.

  Twenty-five patents verified at text level. Ten independent companies. Six countries. 1970–2016. Full record with remarks: In Their Own Words

• Encyclopedia of Reagents for Organic Synthesis. His 1958 paper is listed as Reference 1(a) in the entry for Ethyl Ethoxymethyleneacetoacetate in Wiley's Encyclopedia of Reagents for Organic Synthesis (e-EROS, 2001) — the most consulted synthetic chemistry reference in the discipline.
• Canonical reference works. Antaki's papers appear among the foundational references throughout the standard literature of heterocyclic chemistry.
  • The Chemistry of Heterocyclic Compounds (Weissberger series, Wiley) — cited across four volume-parts under three editors, 1961–1984: the 1951 paper in Klingsberg's Pyridine and Its Derivatives (Parts Two and Three, 1961–62); the 1963 and 1965 papers in Acheson's Vol. 9 (1973), the standard reference for the cyclohexane-1,3-dione / ammonium acetate condensation; the 1963 paper again in Thummel's "Carbocyclic Annelated Pyridines" (Part 5, 1984).
  • Comprehensive Heterocyclic Chemistry (Pergamon) — G. Jones cites the 1963 paper as the sole reference for the cyclohexane-1,3-dione variant of the Hantzsch synthesis (1st ed., 1984); the 2nd edition (1996) draws on the 1951, 1958 and 1962 papers across its treatment of structure, spectroscopy and synthesis.
  • Advances in Heterocyclic Chemistry (Academic Press) — cited by Kuthan (Vol. 34, 1983) and by Hermecz (Vol. 73, 1999); the foundational review by Hermecz and Mészáros (Vol. 33, 1983) calls the 1951 synthesis "unequivocal" and notes it was "first described by Antaki."
  • Houben-Weyl Methoden der Organischen Chemie — the 1951 paper cited in the German canonical synthetic encyclopedia (E 8a, 1993).
  • The Vitamin Co-Factors of Enzyme Systems — the 1951 ribosyl-benzimidazole paper cited in F. A. Robinson's monograph (Pergamon, 1966) in connection with vitamin B₁₂ methodology.
• Modern recognition and citation span. Bonacorso and Zanatta open their synthetic history of the pyrido[1,2-a]pyrimidinone ring system with the 1951 correction as their first reference (J. Heterocyclic Chem. 2006). E. I. Stankevich cited the 1963 paper directly in his own 1967 paper. The 1951 paper's confirmed citation span now reaches 75 years (1951–2026); the 1951 steroid paper remains in active use, cited by Momoli, Arcadi and colleagues as a practical alternative to Vilsmeier–Haack chloroformylation in 2025 (J. Org. Chem. 90, DOI: 10.1021/acs.joc.4c02981) — seventy-four years after publication.
• Queen Mary College London. His doctoral work (1950) and subsequent publications are documented in the alumni record of Queen Mary University of London. Queen Mary University of London — Alumni Remembered: Dr Hekmat Bechir Antaki (1923–1993)
• Wikidata. A Wikidata entity documents his scientific identity and links his eight published papers: Q138809036
• ORCID. Posthumous ORCID record established for H. B. F. Antaki: 0009-0000-9500-1484
• Google Scholar. Publication record indexed by Google Scholar: View profile
• Pentacyclic fluorescent compounds (1967). First synthesis of a fully reduced, intensely blue-fluorescent pentacyclic benz[h]indenoquinoline — a class now studied for OLED materials, bioimaging, and DNA intercalation. Read more →

Scientific Contributions

• Full priority and relevance record: Contributions & Priority
• Named Reaction: The Antaki Synthesis (1963) — Hexahydroquinoline Chemistry

Structural Correction: Resolving a Forty-Year Error

In 1911, Palazzo and Tamburini prepared the first compound in the pyrido[1,2-a]pyrimidine series but assigned it the wrong structure (2-oxo instead of 4-oxo). This error was repeated by Seide (1925) and Crippa & Scevola (1937) and remained in the chemical literature for nearly forty years.

In 1951, Hekmat Bechir Fathallah Antaki, working with V. Petrow at Queen Mary College London, resolved the long-standing error. Using an independent synthesis (reacting 2-bromopyridine with ethyl β-aminocrotonate), they conclusively demonstrated that the correct structure was the 4-oxo isomer — borrowing the words of Hermecz and Mészáros (Advances in Heterocyclic Chemistry, Vol. 33, 1983): "unequivocal synthesis." This assignment was later confirmed by Adams and Pachter (1952) and explicitly credited as the definitive proof by Shur and Israelstam (1968) and by Hermecz and Mészáros, who further noted it was "first described by Antaki" (p. 269).

Ultraviolet Spectroscopy: Establishing the Chromophore Record

In 1958, in his paper to the Journal of the American Chemical Society — submitted from the Research Institute for Tropical Medicine, Cairo, and received October 15, 1957 — Hekmat Bechir Fathallah Antaki published the first systematic ultraviolet absorption spectra of the pyrido[1,2-a]pyrimidine class (J. Am. Chem. Soc. 1958, 80, 3066–3068). He identified a constant feature across all compounds in the class — intense absorption in the region 330–390 mμ — and provided the mechanistic explanation: conjugative interaction with the β-amino-α,β-unsaturated ketone or nitrile chromophore. He further argued, in his own words:

"This may be considered as evidence for the major contribution of zwitterionic fully aromatic structures such as VIII to the resonance state of the molecule."

This is not a recording of spectral data. It is a structural argument — establishing from spectroscopic evidence the electronic character of an entire compound class. The absorption pattern was not random. It was systematic, mechanistically explained, and structurally significant.

His 1962 paper (J. Org. Chem. 1962, 27, 1371–1374) further clarified the mechanistic origin of these bands. Both assignments were independently confirmed by Shur and Israelstam (1968) and were later adopted as the standard reference by Hermecz and Mészáros in their 1983 canonical review.

Together, the 1951 structural correction and the 1958–1962 UV characterization provided the reliable foundation for the pyrido[1,2-a]pyrimidine series. This foundation enabled much of the subsequent chemical development and the pharmaceutical applications that followed in the decades after.

Medical Relevance

The scaffolds Antaki studied later became relevant across several areas of medicinal chemistry.

Cardiovascular. In their 1989 account of the path to nifedipine (Medicinal Research Reviews 9, 291), Bossert and Vater trace the chemistry from khellin through the chromones to the moment "hexahydroquinoline derivatives… aroused our interest" — citing Antaki's 1963 paper (ref. 7) at exactly that step. The hexahydroquinoline was the scaffold immediately preceding the 1,4-dihydropyridine that became nifedipine; Antaki appears again in the synthetic lineage (ref. 13), alongside Knoevenagel (1898). The broader 1,4-dihydropyridine calcium-channel-blocker class includes amlodipine, felodipine and nicardipine.

Antiparasitic. Antaki designed his programme for diseases of resource-limited settings; his 1962 paper noted schistosomicidal activity. The hexahydroquinoline scaffold has since drawn renewed interest in antimalarial drug discovery.

Anticancer / fluorescence. The pentacyclic benz[h]indenoquinoline he first made in 1967 belongs to a class now studied for DNA intercalation, topoisomerase inhibition, and blue-green fluorescence.

The Institution and the Eradication of Malaria in Egypt

In 1954 the Egyptian Ministry of Health constituted the Unit for Study and Eradication of Malaria in Egypt; Antaki joined that year, on returning from London. As malaria declined, the unit's mandate broadened, and in 1961 it became the Research Institute of Medical Entomology — described in its own materials as the only institute in the Arab world specialising in insect-borne diseases and a WHO training centre for vector-borne disease control. Antaki retired as its President in 1983.

Egypt was certified malaria-free by the World Health Organization on 20 October 2024 — seventy years after the institution was founded, forty-one after he left it.

Publications

• Antaki, H.; Petrow, V. J. Chem. Soc. 1951, 901–904. DOI
• Antaki, H.; Petrow, V. J. Chem. Soc. 1951, 551–556. DOI
• Antaki, H.; Petrow, V. J. Chem. Soc. 1951, 2873–2875. DOI
• Antaki, H. J. Am. Chem. Soc. 1958, 80, 3066–3068. DOI
• Antaki, H. J. Org. Chem. 1962, 27, 1371–1374. DOI
• Antaki, H. J. Chem. Soc. 1963, 4877–4879. DOI
• Antaki, H. J. Chem. Soc. 1965, 2263–2264. PDF — Reproduced with the kind permission of the Royal Society of Chemistry.
• Antaki, H. J. Chem. Soc. C 1967, 1581–1582. DOI